Glucagon receptor antagonists-3 are primarily investigated for their potential in managing type 2 diabetes. By blocking the glucagon receptor, these compounds reduce the production of glucose in the liver, helping to lower blood sugar levels. This mechanism is particularly beneficial for patients who struggle with hyperglycemia despite existing treatments. Additionally, these antagonists are being studied for their role in weight management, as they may reduce appetite and promote fat metabolism. Their application could offer a dual benefit in addressing both diabetes and obesity, making them a promising candidate in metabolic disorder therapeutics.